|
gptkbp:instanceOf
|
gptkb:antibiotic
gptkb:drug
|
|
gptkbp:affiliatedWith
|
rifamycins
|
|
gptkbp:approvedBy
|
1992
|
|
gptkbp:ATCCode
|
J04AB04
|
|
gptkbp:bioavailability
|
20%
|
|
gptkbp:CASNumber
|
72559-06-9
|
|
gptkbp:category
|
antineoplastic agent
antimycobacterial agent
|
|
gptkbp:contraindication
|
hypersensitivity to rifamycins
active uveitis
|
|
gptkbp:developedBy
|
gptkb:Lepetit_Pharmaceuticals
|
|
gptkbp:discoveredBy
|
Achille Sensi
|
|
gptkbp:eliminationHalfLife
|
45 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C46H62N4O6
|
|
gptkbp:hasSMILES
|
CC1=C(C(=O)OC2C(C1=O)C3=C(C2O)C(=O)C4=C(C3=O)C(=C(C=C4C)C)C)C5=CC(=C(C=C5)N)N(C)C
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rifabutin
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:clarithromycin
protease inhibitors
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits DNA-dependent RNA polymerase in bacterial cells
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
847.0 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
85%
|
|
gptkbp:PubChem_CID
|
6323494
DB00615
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
rash
neutropenia
uveitis
orange discoloration of body fluids
|
|
gptkbp:synonym
|
Ansamycin LM 427
Mycobutin
|
|
gptkbp:UNII
|
9J8A4823FY
|
|
gptkbp:usedFor
|
treatment of tuberculosis
treatment of Mycobacterium avium complex
|
|
gptkbp:bfsParent
|
gptkb:rifamycin_antibiotics
|
|
gptkbp:bfsLayer
|
6
|